Abstract：
The current article reviews the latest information on epidemiology, clinical features, diagnosis, recent advancements in clinical management, current therapeutic novelties, and the prevention of migraines. In a narrative review, all studies as per developed MeSH terms published until February 2023, excluding those irrelevant, were identified through a PubMed literature search.
Overall, migraine affects more than a billion people annually and is one of the most common neurological illnesses. A wide range of comorbidities is associated with migraines, including stress and sleep disturbances. To lower the worldwide burden of migraine, comprehensive efforts are required to develop and enhance migraine treatment, which is supported by informed healthcare policy. Numerous migraine therapies have been successful, but not all patients benefit from them.
CGRP pathway-targeted therapy demonstrates the importance of translating mechanistic understanding into effective treatment. In this review, we discuss clinical features, diagnosis, and recently approved drugs, as well as a number of potential therapeutic targets, including pituitary adenylate cyclase-activating polypeptide (PACAP), adenosine, opioid receptors, potassium channels, transient receptor potential ion channels (TRP), and acid-sensing ion channels (ASIC).
In addition to providing more treatment options for improved clinical care, a better understanding of these mechanisms facilitates the discovery of novel therapeutic targets.
Overall, migraine affects more than a billion people annually and is one of the most common neurological illnesses. A wide range of comorbidities is associated with migraines, including stress and sleep disturbances. To lower the worldwide burden of migraine, comprehensive efforts are required to develop and enhance migraine treatment, which is supported by informed healthcare policy. Numerous migraine therapies have been successful, but not all patients benefit from them.
CGRP pathway-targeted therapy demonstrates the importance of translating mechanistic understanding into effective treatment. In this review, we discuss clinical features, diagnosis, and recently approved drugs, as well as a number of potential therapeutic targets, including pituitary adenylate cyclase-activating polypeptide (PACAP), adenosine, opioid receptors, potassium channels, transient receptor potential ion channels (TRP), and acid-sensing ion channels (ASIC).
In addition to providing more treatment options for improved clinical care, a better understanding of these mechanisms facilitates the discovery of novel therapeutic targets.
摘要：
背景：本文回顾了有关流行病学的最新信息，临床特征,诊断,临床管理的最新进展，目前的治疗新颖性，以及预防偏头痛。在叙事审查中，截至2023年2月发布的所有已开发的MeSH术语研究，不包括那些不相关的研究，是通过PubMed文献检索确定的。
方法：总的来说，偏头痛每年影响超过10亿人，是最常见的神经系统疾病之一。广泛的合并症与偏头痛有关，包括压力和睡眠障碍。为了减轻全球偏头痛的负担，需要综合努力发展和加强偏头痛的治疗，这得到了知情医疗政策的支持。许多偏头痛疗法已经成功，但并非所有患者都能从中受益。
结果：CGRP途径靶向治疗证明了将机械理解转化为有效治疗的重要性。在这次审查中,我们讨论临床特征，诊断,和最近批准的药物，以及一些潜在的治疗靶点，包括垂体腺苷酸环化酶激活多肽（PACAP），腺苷,阿片受体,钾通道,瞬时受体电位离子通道（TRP），和酸传感离子通道（ASIC）。
结论：除了为改善临床护理提供更多治疗选择之外，更好地理解这些机制有助于发现新的治疗靶点.
方法：总的来说，偏头痛每年影响超过10亿人，是最常见的神经系统疾病之一。广泛的合并症与偏头痛有关，包括压力和睡眠障碍。为了减轻全球偏头痛的负担，需要综合努力发展和加强偏头痛的治疗，这得到了知情医疗政策的支持。许多偏头痛疗法已经成功，但并非所有患者都能从中受益。
结果：CGRP途径靶向治疗证明了将机械理解转化为有效治疗的重要性。在这次审查中,我们讨论临床特征，诊断,和最近批准的药物，以及一些潜在的治疗靶点，包括垂体腺苷酸环化酶激活多肽（PACAP），腺苷,阿片受体,钾通道,瞬时受体电位离子通道（TRP），和酸传感离子通道（ASIC）。
结论：除了为改善临床护理提供更多治疗选择之外，更好地理解这些机制有助于发现新的治疗靶点.
